在HIV-1蛋白质酶中进化的突变积累改变了构造动态,以获得药物耐药性
Michael Souffrant1, Xin-Qiu Yao1, Donald Hamelberg1,2
1Department of Chemistry, Georgia State University, Atlanta, Georgia 30302-3965, United States.
Journal of chemical information and modeling
|June 7, 2023
概括
抗病毒治疗中的耐药性是一个主要问题. 像HIV-1蛋白酶这样的病毒蛋白中的突变可以通过改变蛋白质动态和阻碍药物结合,影响治疗有效性,从而导致耐药性.
科学领域:
- 分子生物学分子生物学
- 病毒学 病毒学
- 生物物理学的生物物理.
背景情况:
- 抗病毒疗法中的耐药性构成了重大的公共卫生挑战.
- 人类免疫缺陷病毒I型 (HIV-1) 蛋白酶是抗逆转录病毒药物的关键标,但通过病毒突变产生耐药性.
- 确切的机制,HIV-1蛋白酶突变赋予耐药性仍然不完全理解.
研究的目的:
- 调查HIV-1蛋白酶突变改变其构造组合,削弱药物结合并导致耐药性的假设.
- 阐明HIV-1蛋白酶变体中药物耐药性的详细分子机制.
主要方法:
- 对野生型和耐药HIV-1蛋白酶变体进行了超过30微秒的广泛分子动力学 (MD) 模拟.
- 对形状组合进行比较分析,以确定与功能相关的动态变化.
- 增强差异联系网络社区分析以探测全性通信通路.
主要成果:
- 耐药HIV-1蛋白酶变体的结构动态与野生类型有显著差异.
- 改变的膜动态被确定为阻碍活跃部位访问的药物耐药性的主要驱动因素.
- 最耐药的变种表现出"崩"的活性部位口袋,显著阻碍了药物结合.
结论:
- 艾滋病毒-1蛋白酶的突变会动态改变蛋白质结构,导致药物的疗效降低.
- 特定的突变在增加耐药性和恢复病毒健康方面发挥着独特的作用.
- 这项研究提供了一个框架,通过分析蛋白质动态来理解和潜在地克服抗病毒药物耐药性.
更多相关视频
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
14.4K
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
15.7K
相关概念视频
Viral Mutations
32.6K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.6K
Mutations in Microorganisms
36
Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
36
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Retrovirus Life Cycles
46.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.3K
Spontaneous and Induced Mutations
47
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
47
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
